Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

JAMA

Volumn 280, Issue 1, 1998, Pages 67-71

  Schrager, Lewis K ^a   D'Souza, M Patricia ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD;

EID: 0032122490     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.1.67     Document Type: Article

References (62)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
3. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387: 188-191
4. Folks T, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol. 1986;136:4049-4053.
5. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61:213-222.
6. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoirin HIV-1 infection. Science. 1991; 254:423-427.
7. Bukrinsky MI, Sharova N, Dempsey MP, et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A. 1992;89:6580-6584.
8. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284-1290.
9. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360:264-265.
10. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
11. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
12. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197.
13. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
14. Siliciano RF. Molecular analysis of latent viral reservoirs in HIV-1 infection. Conference presentation at: Keystone Symposia: HIV Pathogenesis and Treatment; March 15, 1998; Park City, Utah.
15. + T cells. Science. 1995;270:1811-1815.
16. + T cells. Immunol Today. 1996;17:217-224.
17. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106.
18. Ho D. Residual pool of HIV after prolonged combination therapy. Conference presentation at: 5th Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, Ill.
19. + T cell responses associated with control of viremia. Science. 1997; 278:1447-1450.
20. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
21. Fauci A. Host factors in the pathogenesis of HIV disease: role of cellular activation and cell signaling. Conference presentation at: 5th Conference on Retroviruses and Opportunistic Infections; February 4, 1998; Chicago, Ill.
22. Meltzer MS, Nakamura M, Hansen BD, Turpin JA, Kalter DC, Gendelman HE. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res Hum Retroviruses. 1990; 6:967-971.
23. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233:1089-1093.
24. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233:215-219.
25. Moreno P, Rebollo MJ, Pulido F, Rubio R, Noriega AR, Delgado R. Alveolar macrophages are not an important source of viral production in HIV-1 infected patients. AIDS. 1996;10:682-684.
26. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest. 1986;77:1712-1715.
27. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science. 1997;276:1857-1861.
28. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
29. van Furth R. Origin and turnover of monocytes and macrophages. Curr Top Pathol. 1989;79:125-150.
30. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-362.
31. Perno C-F, Newcomb FM, Davis DA, et al. Relative potency of protease inhibitors in macrophages chronically-infected by HIV-1. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 639.
32. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
33. Kaczorowski S, Ochocka M, Kaczorowska M, Aleksandrowicz R, Matysiakl M, Karwacki M. Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome. Leuk Lymphoma. 1995;20:143-152.
34. Lee CG, Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest. 1998;101:287-288.
35. Picker LJ, Siegelman MH. Lymphoid tissues and organs. In: Paul WE, ed. Fundamental Immunology. 3rd ed. New York, NY: Raven Press Ltd; 1993: 145-197.
36. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA [published erratum appears in J Infect Dis. 1992;165:1161]. J Infect Dis. 1991;164:1051-1057.
37. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
38. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-989.
39. Pantaleo G, Graziosi C, Demarest JF, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev. 1994;140:105-130.
40. Heath SL, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 1995;377:740-744.
41. Burton GF. Follicular dendritic cell (FDC): maintenance of infectivity. In: Program and abstracts of the Institute of Human Virology 2nd Annual Meeting; September 15-21, 1997; Baltimore, Md. Abstract 142.
42. Cohen OJ, Pantaleo G, Holodniy M, et al. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis. 1996;173:849-856.
43. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection [published erratum appears in Science. 1997;276:1321]. Science. 1997; 276:960-964.
44. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997;94:12574-12579.
45. Haase A. Measures of reality. Conference presentation at: 5th Conference on Retroviruses and Opportunistic Infections; February 1, 1998; Chicago, Ill.
46. Phipps RP, Mandel TE, Tew JG. Effect of immunosuppressive agents on antigen retained in lymphoid follicles and collagenous tissue of immune mice. Cell Immunol. 1981;57:505-516.
47. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol. 1993; 33:429-436.
48. Gabuzda DH, Hirsch MS. Neurologic manifestations of infection with human immunodeficiency virus: clinical features and pathogenesis. Ann Intern Med. 1987;107:383-391.
49. Kure K, Llena JF, Lyman WD, et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991;22:700-710.
50. Pratt RD, Nichols S, McKinney N, Kwok S, Dankner WM, Spector SA. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. J Infect Dis. 1996;174: 288-293.
51. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis. 1996;174:1200-1206.
52. Ellis RJ, Spector SA, Hsia K, et al. HIV-1 viral dynamics differ in cerebrospinal fluid and plasma. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 453.
53. Clements J. CD4-independent virus entry: a key mechanism for infection of the CNS. Conference presentation at: 5th Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, Ill.
54. Pomerantz RJ, Kuritzkes DR, de la Monte SM, et al. Infection of the retina by human immunodeficiency virus type I. N Engl J Med. 1987;317:1643-1647.
55. Cunningham P, Smith D, Satchell C, Cooper DA, Brew B. In vivo comparison of RT inhibitor resistance patterns in paired cerebrospinal fluid and blood of HIV-1 infected patients with a novel line probe assay. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 682.
56. Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:1167-1171.
57. Haworth SJ, Christofalo B, Anderson RD, Dunkle LM. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:235-238.
58. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis. 1996; 174:16-25.
59. Stahle L, Martin C, Svensson JO, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients [letter]. Lancet. 1997;350:1823.
60. Roth V, Kravcik S, Garber G, et al. Correlation of plasma and cerebrospinal fluid HIV RNA quantitation in protease inhibitor anti-HIV treatment. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 329.
61. Schlegel PN, Chang SK. Physiology of male reproduction: the testes, epididymis, and ductus deferens. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. 7th vol. Campbell's Urology. Philadelphia, Pa: WB Saunders Co; 1998:1254-1286.
62. Pomerantz RJ. HIV-1 in seminal fluid and cervical secretions: potential reservoirs for HIV-1 in vivo. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 562.